drugset
drugset / Trial / NCT00052949

Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00052949 ↗

Phase 2 Completed 91 enrolled National Cancer Institute (NCI) Cancer and Leukemia Group B · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent small cell lung cancer. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

Timeline

Start
2003-05
Primary completion
2007-10
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule — Oral

Indications

small cell lung carcinoma